Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who ...

Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study,” published in the March 2025 issue of Journal of the ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

Antibiotic nonsusceptibility and MDR-E infections were consistently more prevalent among adult HSCT recipients than in those with no history of HSCT.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...